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Research
AbstrACt
Objective Treatment options for severe, enduring 
anorexia nervosa (SE-AN) are limited. Non-invasive 
neuromodulation is a promising emerging intervention. 
Our study is a feasibility randomised controlled trial of 
repetitive transcranial magnetic stimulation (rTMS) in 
individuals with SE-AN, which aims to inform the design of 
a future large-scale trial.
Design Double-blind, parallel group, two-arm, sham-
controlled trial.
setting Specialist eating disorders centre.
Participants Community-dwelling people with anorexia 
nervosa, an illness duration of ≥3 years and at least one 
previous completed treatment.
Interventions Participants received 20 sessions 
(administered over 4 weeks) of MRI-guided real or sham 
high-frequency rTMS to the left dorsolateral prefrontal 
cortex in addition to treatment-as-usual.
Outcomes Primary outcomes were recruitment, 
attendance and retention rates. Secondary outcomes 
included body mass index (BMI), eating disorder 
symptoms, mood, quality of life and rTMS safety and 
tolerability. Assessments were conducted at baseline, 
post-treatment and follow-up (ie, at 0 month, 1 month and 
4 months post-randomisation).
results Thirty-four participants (17 per group) were 
randomly allocated to real or sham rTMS. One participant 
per group was withdrawn prior to the intervention due to 
safety concerns. Two participants (both receiving sham) 
did not complete the treatment. rTMS was safe and well 
tolerated. Between-group effect sizes of change scores 
(baseline to follow-up) were small for BMI (d=0.2, 95% CI 
−0.49 to 0.90) and eating disorder symptoms (d=0.1, 
95% CI −0.60 to 0.79), medium for quality of life and 
moderate to large (d=0.61 to 1.0) for mood outcomes, all 
favouring rTMS over sham.
Conclusions The treatment protocol is feasible and 
acceptable to participants. Outcomes provide preliminary 
evidence for the therapeutic potential of rTMS in SE-AN. 
Largest effects were observed on variables assessing 
mood. This study supports the need for a larger 
confirmatory trial to evaluate the effectiveness of multi-
session rTMS in SE-AN. Future studies should include 
a longer follow-up period and an assessment of cost-
effectiveness.
trial registration number ISRCTN14329415; Pre-results.
IntrODuCtIOn 
Anorexia nervosa (AN) is a life-threatening 
disorder of multifactorial aetiology. Alter-
ations in neural circuits involved in reward 
processing, negative affect and stress, appe-
tite regulation, cognitive (self-regulatory) 
control and socioemotional processes have 
been implicated in its causation and mainte-
nance.1 2 
Approximately 20% of patients develop a 
severe, enduring form of illness (SE-AN).3 
strengths and limitations of this study
 ► This is the first randomised controlled feasibility tri-
al of multi-session repetitive transcranial magnetic 
stimulation (rTMS) treatment in people with anorexia 
nervosa (AN).
 ► It targeted those with severe and enduring AN 
(SE-AN).
 ► A range of outcomes were assessed (recruitment, 
retention, safety, tolerability and effect sizes of clin-
ical outcome variables); thus, it provides useful data 
for implementing a larger scale randomised con-
trolled trial of rTMS in SE-AN.
 ► The study had a small sample size, was not powered 
or designed to assess the efficacy of rTMS in SE-AN 
and the follow-up duration was short.
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These patients typically have high levels of depression 
and anxiety, are socially isolated and markedly impaired 
in their ability to care for themselves. In fact, their quality 
of life is comparable with that of patients with depres-
sion and impairments in social contact and self-care are 
comparable with those in psychosis.4 Recent research on 
treatments for AN has mainly focused on psychological 
therapies.5 Only two small trials have focused on SE-AN, 
using psychological therapies or medication to improve 
quality of life6 or achieve weight gain, although with 
limited success.7 Thus, there is a need for novel interven-
tions for this group.1 5 6 8
Non-invasive neuromodulation is a promising 
emerging treatment for SE-AN,2 5 9 in particular 
repetitive transcranial magnetic stimulation (rTMS) 
(eg, 10 11). rTMS can enhance (high-frequency) or 
inhibit (low-frequency) cortical activity in targeted 
brain areas. It appears to increase neuroplasticity, and 
hence may be of value in chronic or treatment-resis-
tant neurocircuit-based disorders, such as SE-AN.9 
Based on the Research Domain Criteria, candidate 
targets for rTMS in eating disorders (EDs) have been 
described, involving brain structures/circuitry in the 
cognitive control, positive and negative valence, and 
social processes systems.12 Partly for theoretical reasons, 
but also for accessibility reasons, rTMS studies have 
targeted the dorsolateral prefrontal cortex (DLPFC) or 
the dorsomedial prefrontal cortex.12
Proof-of-concept studies have shown that rTMS is a 
promising treatment in AN.9 12 We previously carried out 
two single-session studies in AN13 14 and a case series of 
20 sessions of rTMS in SE-AN,11 15 all involving high-fre-
quency rTMS to the left DLPFC. These studies showed 
that rTMS can lead to both short-term and long-term 
improvements in ED symptoms, mood and reward-based 
decision making. Thus, there is a rationale for further 
exploring the therapeutic potential of rTMS in SE-AN.
To date, no sham-controlled randomised controlled 
trial (RCT) of rTMS in SE-AN has been conducted. The 
present trial (Transcranial Magnetic Stimulation and 
Neuroimaging in Anorexia Nervosa) aimed to assess the 
feasibility of using rTMS compared with sham treatment 
in people with SE-AN and to inform the development of a 
large-scale sham-controlled RCT.16 Our primary objective 
was:
a. To assess recruitment, attendance and retention rates.
Secondary objectives were:
a. To estimate the treatment effect sizes and standard de-
viations  for outcome measures to inform future sam-
ple size calculations.
b. To determine safety and tolerability of rTMS in SE-AN.
Subsidiary objectives were to assess neuropsychological 
and neural correlates and predictors of rTMS treatment 
in AN and to assess within-session change processes. Find-
ings relating to these will be published elsewhere. The 
study rationale, aims and tentative hypotheses, along with 
the trial design and methodology are described fully in a 
protocol paper.16
MethODs
Design, participants and setting
In a double-blind parallel group, randomised controlled 
design, participants were allocated to receive 20 sessions 
of either real or sham high-frequency rTMS in addition 
to treatment-as-usual (TAU). Outcomes were assessed at 
baseline (pre-randomisation), post-treatment (~1 month 
post-randomisation) and at follow-up (~4 months 
post-randomisation).
Right-handed community-dwelling adults (≥18 years 
old) with a current Diagnostic and Statistical Manual 
of Mental Disorders (5th edition17 [DSM-5]) diagnosis 
of AN and a body mass index (BMI) >14 kg/m2 were 
eligible. Participants had to have a severe, enduring form 
of AN; this was defined as an illness duration of ≥3 years 
and completion of at least one previous course of treat-
ment (eg, National Institute for Health and Care Excel-
lence [NICE18]-recommended specialist psychotherapy 
or specialist day-patient or inpatient treatment for their 
ED) (We accept that there is a continuing debate on defi-
nitions of SE-AN; for review, see Broomfield et al.19). To 
take part, participants needed agreement from their ED 
clinician or general practitioner. Main exclusion criteria 
were related to contraindications to either rTMS or MRI 
(for details, see 16).
Participants were recruited from the Eating Disorders 
Unit at the South London and Maudsley NHS Founda-
tion Trust, through online and media advertisements and 
through participation in other research projects.
Potential participants underwent a screening proce-
dure to determine eligibility (see 16 for details). Once 
eligibility was determined, participants’ written informed 
consent was obtained prior to the baseline assessment.
randomisation and blinding
Randomisation was conducted by the King’s College 
London (KCL) Clinical Trials Unit (CTU) using their 
automatic online system. Randomisation requests were 
submitted by study researchers via the web-based CTU 
system after the baseline assessment. Participants were 
allocated at a ratio of 1:1 to the two trial arms using a 
restricted stratified randomisation algorithm stratifying 
by prognostic factors: AN subtype (AN restrictive or 
AN binge–purge) and intensity of TAU (high: day-patient 
treatment, or low: outpatient or no treatment). The strat-
ification was implemented by minimised randomisation 
with a random component. The first n cases (n was not 
disclosed) were allocated entirely at random to further 
enhance allocation concealment.
Participants and researchers were blinded to treatment 
allocation, except for one researcher who conducted 
follow-up assessments and unblinded participants. For 
practical reasons, a small proportion of rTMS sessions 
(116/594 sessions; 19.53%) was delivered by the 
unblinded researcher. All other rTMS therapists remained 
blinded until study data had been collected and analysed. 
Participants were unblinded at 4 months post-randomisa-
tion once they had completed the study. Participants who 
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received the sham intervention were offered real rTMS 
(if they continued to meet eligibility criteria) after their 
follow-up. Assessments of blinding success were carried 
out for rTMS therapists and participants. For details, see 
online supplementary information.
Intervention
Participants received 20 sessions of (real or sham) 
high-frequency rTMS to the left DLPFC over 20 consecu-
tive weekdays, in addition to TAU (ie, specialist ED outpa-
tient or day-patient treatment, or no current treatment). 
Each session lasted 30–60 minutes, including preparation 
time, 20 minutes of rTMS and administration of with-
in-session measures. rTMS sessions were conducted at the 
Institute of Psychiatry, Psychology & Neuroscience, KCL, 
in a designated rTMS suite.
Prior to starting treatment, all participants underwent 
a structural MRI scan to localise the DLPFC (Talairach 
co-ordinates x=−45, y=45, z=30)11 20 for the purpose of 
neuronavigation (using Brainsight neuronavigation 
software). To determine the intensity of the rTMS stim-
ulation, a Magstim Rapid device (Magstim, Whitland, 
Wales, UK) with a real TMS figure-of-eight coil was used 
to determine participants’ motor threshold (MT), which 
represents membrane-related excitability of cortical 
axons. Using the motor-evoked potential method, the MT 
was established by determining the minimum stimulator 
output intensity required to obtain 5 out of 10 motor-
evoked potentials >50 μV. MT was acquired weekly for 
each participant to ensure accuracy of the rTMS dose.
The Magstim Rapid device and Magstim D70-mm 
air-cooled real and sham coils were used to administer real 
and sham rTMS. Participants in the real group received 
20 sessions of high-frequency (10 Hz) rTMS at 110% of 
their individual MT, consisting of 20 5 s trains with 55 s 
inter-train intervals delivered to the left DLPFC (a total 
of 1000 pulses delivered over each 20 minute session).11 20 
Sham stimulation was administered at the same param-
eters as real rTMS; however, a sham coil was used. The 
sham coil produces the same noises and feelings as the 
real coil but does not deliver active stimulation to the 
brain, rather it stimulates facial and scalp nerves.
Outcomes
The primary outcomes to assess feasibility were recruit-
ment, attendance and retention rates. To judge whether 
or how to proceed with a future definitive trial, we 
prespecified two criteria: first, recruitment as planned 
(see protocol paper16 and the ‘Changes to planned 
protocol’ section below), and second, research follow-up 
rates of ≥80% at 4 months post-randomisation. We did not 
prespecify any rTMS session attendance rates required 
for progression to a full trial, but clearly these would also 
guide a decision about the feasibility of a future trial. 
rTMS session attendance was recorded using a specially 
designed case record form.
Secondary feasibility outcomes included a range of 
clinical measures administered at baseline, 1 month 
(post-treatment) and 4 months post-randomisation 
(follow-up) to assess ED symptomatology, mood, other 
psychopathology and quality of life. Neurocognitive 
and neuroimaging assessments of rTMS treatment 
(see protocol paper16) were also completed but will be 
presented elsewhere.
ED symptomatology
The outcome measures used were BMI, the Eating Disorder 
Examination Questionnaire version 6.0,21 the Fear of 
Food Measure,22 the Self-Starvation Scale23 and the Eating 
Disorder Recovery Self-Efficacy Questionnaire.24
Mood and other psychopathology
The measures used included the Depression, Anxiety and 
Stress Scale – 21 item (DASS-21),25 the Positive and Nega-
tive Affect Schedule,26 the Profile of Mood States27 and 
the revised Obsessive-Compulsive Inventory.28
Quality of life
The measures used were the EuroQol Quality of Life 
Scale (5-level EQ-5D version; EQ-5D-5L)29 and the Clin-
ical Impairment Assessment.30 31
In light of the prominent mood and quality of life 
component of SE-AN, and the association between 
these two variables in SE-AN,4 the clinical outcome to be 
assessed as a primary outcome in a future definitive trial 
would most likely be the DASS.25
Additional service utilisation
Patients’ additional service utilisation was assessed with a 
self-report version of the Clinical Service Receipt Inven-
tory32 and a specially designed case record form.
Safety, tolerability and participants’ experience of treatment
To ensure safety, participants’ weight, blood pressure 
(sitting and standing) and pulse were monitored weekly. 
Routine blood tests (including full blood count, urea 
and electrolytes and renal and liver function tests) were 
conducted prior to the start of rTMS treatment and were 
repeated at the midpoint of treatment or more frequently 
if clinically indicated. rTMS-associated side effects and 
participants’ expectations and experience of treatment 
were also assessed (see online supplementary files).
Procedure
Full details of the procedures and a table of measures-by-as-
sessment are presented in our protocol paper.16 All proce-
dures were identical between groups, except for the rTMS 
intervention.
Baseline assessment and rTMS sessions
Participants’ weight and height were measured, and 
they completed a battery of questionnaires (described 
above) and neuropsychological computer tasks (not 
presented here). A 1-hour MRI scan was also conducted. 
This included a structural MRI (for rTMS target locali-
sation), functional MRI (fMRI), resting state fMRI and 
arterial spin labelling (not reported here). Thereafter, 
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participants were randomly allocated to real or sham 
rTMS treatment.
All rTMS procedures and parameters were in accor-
dance with the current safety and application guide-
lines for rTMS.33 Treatment was delivered by researchers 
trained in rTMS administration.
Each rTMS session (except session 1) started with assess-
ment of any side effects experienced since the previous 
session. Within-session ED cognitions were measured with 
VAS (relating to subsidiary aims, published separately), 
completed following brief cue exposure (ie, film clip of 
highly palatable foods) immediately before and after 
each rTMS session.
Post-treatment assessment (1 month post-randomisation)
The post-treatment assessment occurred within 1 week of 
the final rTMS session and included the same elements as 
the baseline assessment.
Follow-up (4 months post-randomisation)
This final assessment repeated the post-treatment assess-
ment, except no MRI scan was conducted. In this session, 
an audio-recorded qualitative semi-structured interview 
was undertaken to ascertain participants’ views on and 
experience of rTMS (published in full elsewhere), and 
blinding success was evaluated. Participants were then 
unblinded and individuals in the sham rTMS group were 
offered real rTMS treatment.
Changes to planned protocol
We planned to recruit 44 participants but revised this to 
30 participants because a greater than anticipated propor-
tion of potential participants were not eligible (eg, due 
to MRI/rTMS contraindications or being left-handed). 
These figures are in line with recommendations for feasi-
bility trials34 and accounted for attrition. Additionally, we 
removed the upper BMI limit (18.5 kg/m2) to reflect the 
change in diagnostic criteria for AN in DSM-5.17
Patient and public involvement (PPI)
In preparation for the present study, we asked partici-
pants in our previous proof-of-concept studies on rTMS 
in EDs whether they would be interested in undergoing 
a full course of rTMS treatment, with the vast majority 
(41/47; 87%) answering affirmatively.14 35 In 2013, our 
early studies in rTMS were featured in a BBC TV docu-
mentary, and following this, approximately 50 people 
with AN or their relatives contacted us as they were keen 
to have rTMS treatment, even if they had to travel. Many 
people who contacted us had SE-AN, with multiple unsuc-
cessful previous treatments. This shows that there is an 
unmet need in relation to treatments for SE-AN and that 
patients with SE-AN and their carers see rTMS as a treat-
ment to be prioritised in research.
In planning the present study, discussions with patients/
carers influenced our study design as follows: first, we 
were originally concerned that daily rTMS treatment over 
4 weeks might be too burdensome. However, our PPI advi-
sors thought this to be acceptable. Second, participant 
feedback emphasised the importance of including a 
broad range of outcome measures, rather than a narrow 
focus on weight and eating. Third, it encouraged us to 
include a sham control condition in the study so as to 
not create unfounded expectations of success that may 
be based on a placebo response. The completed study 
protocol was reviewed and enthusiastically endorsed by 
one person with AN who had participated in our previous 
rTMS case series11 and another made minor comments, 
which were incorporated.
Participant experience of rTMS treatment and other 
aspects of the current study, including assessment and 
treatment burden, were assessed with qualitative inter-
views at follow-up, as briefly described above. Data will be 
reported elsewhere and will inform future rTMS trials in 
AN.
An expert by experience and a carer of a person with 
AN were part of our trial steering group and reviewed and 
advised on the conduct of the study, its dissemination and 
future trial design. A summary of the results of the study 
has been sent to all study participants, and they will be 
provided with a copy of this article.
Data analysis
Primary feasibility outcomes are presented as n/N (%). 
The post-treatment and follow-up group means and 
standard deviations (SD) for secondary outcomes were 
adjusted for baseline and presented with effect sizes 
(Cohen’s d) alongside 95% confidence intervals (CIs). 
Last observation carried forward imputation was used for 
missing data.
results
Patient flow, attendance and retention
Patient flow is shown in the Consolidated Standards of 
Reporting Trials diagram (figure 1), and the primary 
feasibility outcome findings are described below. The trial 
duration was determined by the funding period.
During the 20-month recruitment period (August 2015–
March 2017), 269 people expressed interest in the study. 
Of these, 61 (22.7%) did not meet the inclusion criteria 
and 81 (30.1%) were not interested and/or declined to 
participate, with the majority citing trial practicalities as 
a reason for this (eg, accessibility, financial limitations, 
time commitment). Thirty-four people were enrolled and 
randomly allocated to the two treatment arms (n=17 per 
group). Two randomised participants were withdrawn 
for safety reasons prior to starting treatment: one partic-
ipant (allocated to sham rTMS) had a syncope during 
her initial MT assessment; the other patient’s (allocated 
to real rTMS) weight had dropped below BMI 14 kg/m2. 
These participants were excluded from the analyses. All 
others were included.
Thirty-two participants started treatment; two partic-
ipants allocated to sham rTMS stopped treatment, one 
after four sessions (due to anxiety with travel) and one 
after nine sessions (due to multiple commitments). All 
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other participants (n=30) completed treatment (defined 
a priori as ≥17 sessions of rTMS, n=18 attended the full 
20 sessions) and all three study assessments, which gave a 
retention rate of 93.75% (30/32).
Baseline demographics and clinical characteristics are 
presented in table 1. All participants were female and had 
a long-standing illness, having previously spent a mean of 
nearly 11 months as an inpatient for their ED.
treatment effect sizes
The means, standard deviations and between-group 
treatment effect sizes (with confidence intervals) for 
change scores (baseline to post-treatment and baseline 
to follow-up) of the secondary clinical outcomes are 
presented in table 2. Group differences in BMI and ED 
symptoms were of small effect at both post-treatment 
and follow-up but favoured active treatment. At 4 months 
Figure 1 CONSORT diagram of participant involvement. CONSORT, Consolidated Standards of Reporting Trials; SLaM EDU, 
South London and Maudsley NHS Foundation Trust Eating Disorders Unit; NHS, National Health Service; rTMS, repetitive 
transcranial magnetic stimulation.
 o
n
 10 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021531 on 16 July 2018. Downloaded from 
6 Dalton B, et al. BMJ Open 2018;8:e021531. doi:10.1136/bmjopen-2018-021531
Open access 
Table 1 Baseline demographics and clinical characteristics
Whole sample Real rTMS Sham rTMS
N N N
Demographic details
Age (mean [SD]) 34 29.74 (10.35) 17 28.47 (9.48) 17 31.00 (11.29)
Highest level of education achieved 33 17 16
  GCSE 3 2 1
  AS levels and above 30 15 15
Ethnicity 34 17 17
  White 31 16 15
  Other 3 1 2
Marital status 34 17 17
  Single 26 13 13
  Married 6 4 2
  Divorced 1 0 1
  Other 1 0 1
Clinical characteristics
Diagnosis 34 17 17
  AN-R 22 11 11
  AN-BP 12 6 6
BMI, kg/m2 (mean [SD]) 33 16.00 (1.44) 17 15.76 (1.62) 16 16.26 (1.22)
Duration of illness, years (mean [SD]) 34 14.07 (10.75) 17 13.74 (10.74) 17 14.41 (11.09)
Number of previous ED 
hospitalisations (mean [SD])
34 2.18 (1.91) 17 2.47 (2.07) 17 1.88 (1.76)
Number of previous ED inpatient 
stays, months (mean [SD])
33 10.49 (11.66) 17 12.37 (12.46) 16 8.50 (10.78)
Previous course (≥1) of ED outpatient 
treatment
29 14 15
Previous course (≥1) of ED day-patient 
treatment
19 10 9
Current treatment 34 17 17
  Receiving ED day-patient treatment 2 1 1
  Receiving ED outpatient treatment 25 13 12
  Receiving no treatment 7 3 4
  Antidepressant medication 21 11 10
  Other psychotropic medication 7 2 5
   Antipsychotic medication 4 1 3
   Benzodiazepine/other anxiolytic/
sedative medication
4 2 2
EDE-Q Global (mean [SD]) 33 4.16 (1.11) 17 4.07 (1.28) 16 4.25 (0.94)
EDE-Q Restraint Subscale (mean [SD]) 33 3.99 (1.54) 17 3.87 (1.46) 16 4.11 (1.65)
EDE-Q Eating Concern Subscale 
(mean [SD])
33 3.65 (1.21) 17 3.59 (1.45) 16 3.71 (0.93)
EDE-Q Shape Concern Subscale 
(mean [SD])
33 4.68 (1.31) 17 4.58 (1.55) 16 4.78 (1.03)
EDE-Q Weight Concern Subscale 
(mean [SD])
33 4.33 (1.25) 17 4.28 (1.33) 16 4.38 (1.20)
CIA Total (mean [SD]) 33 43.64 (11.36) 17 43.35 (12.72) 16 43.94 (10.12)
Continued
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post-randomisation, there were between-group differ-
ences of medium to large effect size in measures of mood, 
obsessive compulsive symptoms and quality of life, all 
favouring the active treatment. The adjusted means for 
the planned future primary outcome, DASS total score, 
were −21.25 (SD 24.33) in the real intervention group 
and −3.75 (SD 12.75) in the sham group, with a between-
group effect size of d=−0.9 (95% CI −1.62 to −0.17).
At baseline, 25 participants received outpatient treat-
ment and 5 were not receiving treatment. One partic-
ipant per group received day-patient treatment. A high 
proportion of participants were taking antidepressants 
and remained on this at a stable dose throughout the 
trial. Participants’ utilisation of TAU is shown in table 1.
At follow-up, the two participants originally in day-pa-
tient treatment were instead receiving outpatient treat-
ment. Three participants had increased treatment 
intensity at follow-up, with two (one per group) starting 
inpatient treatment and one (from the real group) starting 
day-patient treatment. Of the remaining participants, two 
initially receiving no treatment started outpatient treat-
ment and eight decreased intensity from outpatient treat-
ment to no treatment.
Of those who completed the sham intervention, 71% 
took up the offer of having real rTMS treatment.
safety
In addition to the one withdrawn participant whose 
weight dropped below range prior to starting treatment, 
one other participant’s weight (from the real group) 
was recorded below BMI 14 kg/m2 (13.80 kg/m2) in 
their final rTMS session. No other participants’ weight 
fell below the required BMI range for the duration of 
treatment. Blood pressure and pulse measurements did 
not raise any undue concerns during the study. One 
participant had lowered baseline potassium and start of 
treatment was delayed by 1 week. Blood samples for the 
remaining participants raised no major concerns, that is, 
termination or postponing of treatment was not required. 
For side effects experienced, see online supplementary 
table 1.
DIsCussIOn
Principal findings
The main findings relate to the primary feasibility objec-
tives of this study. We were able to recruit participants 
as planned, after making an adjustment to recruitment 
numbers. Many people interested in the trial could not 
be recruited as travelling to London for rTMS sessions 
proved impractical. A future trial therefore needs to 
consider offering treatment in several centres with easy 
transport access. Research follow-up rates exceeded our 
prespecified criterion of ≥80%. Treatment session atten-
dance was excellent in both groups. Although for prag-
matic reasons, and compared with others, our definition 
of ‘severe, enduring AN’ was lenient,19 we managed to 
recruit and retain a very chronic and treatment-refractory 
population.
In relation to our secondary feasibility objectives, there 
were large between-group effect sizes on change scores 
from pre-treatment to follow-up on several mood vari-
ables (eg, DASS global score d=−0.9, 95% CI –1.62 to 
−0.17), favouring real rTMS. Comorbid depression is 
common in AN and has been shown to be associated with 
poor quality of life in people with SE-AN.4 The impor-
tance of improving quality of life in SE-AN, rather than 
focusing on changing ED symptoms and weight gain has 
been emphasised,36 and the improvements in depres-
sion observed here may contribute to the broader aim of 
enhancing quality of life in this group. Also, given that anti-
depressants are typically not very effective in underweight 
populations or have unacceptable side effects,1 rTMS may 
provide an alternative treatment for common comorbid 
symptoms such as depression and anxiety. Within the 
current study, a higher proportion of participants were 
Whole sample Real rTMS Sham rTMS
N N N
EQ-5D-5L: how good or bad is your 
health today? (mean [SD])
33 48.91 (17.44) 17 47.47 (18.63) 16 50.44 (16.55)
DASS-21 Depression (mean [SD]) 33 26.12 (9.68) 17 26.82 (9.44) 16 25.38 (10.19)
DASS-21 Anxiety (mean [SD]) 33 15.39 (10.29) 17 14.82 (8.31) 16 16.00 (12.31)
DASS-21 Stress (mean [SD]) 33 26.91 (7.92) 17 28.35 (7.12) 16 25.38 (8.66)
DASS-21 Total (mean [SD]) 33 68.42 (24.52) 17 70.00 (20.59) 16 66.75 (28.72)
POMS Total Mood Disturbance (mean 
[SD])
33 83.97 (36.75) 17 81.41 (36.84) 16 86.69 (37.66)
OCI-R total (mean [SD]) 33 27.79 (16.97) 17 24.00 (16.48) 16 31.81 (17.05)
SD, standard deviation; GCSE, General Certificate of Secondary Education; AS, Advanced Subsidiary; AN-BP, anorexia nervosa binge–purge 
subtype; AN-R, anorexia nervosa restrictive subtype; CA, California; CIA, Clinical Impairment Assessment; DASS-21, Depression, Anxiety and 
Stress Scale – 21 items; ED, eating disorder; EDE-Q, Eating Disorder Examination Questionnaire; EQ-5D-5L, EuroQol Quality of Life Scale; 
POMS, Profile of Mood States; OCI-R, revised Obsessive-Compulsive Inventory; rTMS, repetitive transcranial magnetic stimulation.
Table 1 Continued 
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taking antidepressant medication (61.7%; 21/34 partic-
ipants) and somewhat higher depression scores were 
observed, compared with other treatment studies of 
AN.37 38 This may suggest that either our participants had 
particularly high levels of comorbid depression or that 
we attracted participants who were particularly drawn to 
‘physical/biologically targeted treatments’ rather than 
psychological treatments. Having said that, many partici-
pants had previously undertaken unsuccessful psycholog-
ical treatments.
We considered that rTMS may be interacting with the 
actions of the medication to produce this antidepressant 
effect; however, there is no evidence for this mechanism 
in the depression literature. Developing better evidence 
for the treatment of comorbidities in EDs is a research 
recommendation in the recent NICE guidelines18 and, 
therefore, our study potentially fills an important gap.
In addition to the mood effects, there were medium 
between-group effect sizes on follow-up change scores 
in quality of life (d=0.52, 95% CI −0.19 to 1.22), whereas 
between-group effect sizes on change scores for BMI 
(d=0.2, 95% CI −0.49 to 0.90) and ED symptoms (d=0.1, 
95% CI −0.60 to 0.79) were small. Larger between-group 
effect sizes were seen on change scores from pre-treat-
ment to follow-up than to post-treatment, suggesting 
that changes develop over time, rather than being due 
to immediate effects of rTMS. A similar delay in effect 
was observed in our previous case series of rTMS in 
SE-AN.11 rTMS was safe, well tolerated and considered to 
be an acceptable treatment by participants. These various 
findings suggest that it is feasible to conduct a future 
larger scale therapeutic RCT with a sham-controlled 
design to establish the therapeutic efficacy of rTMS in 
SE-AN.
strengths and limitations
Our study has several strengths. It is the first RCT of 
multi-session rTMS treatment in individuals with AN. 
Second, it focused on people with severe, enduring 
illness. As such, it adds to the limited number of studies 
that have specifically targeted people with SE-AN. Third, 
it was sham-controlled, which is considered the gold stan-
dard method of evaluating the clinical efficacy of rTMS 
treatment.39 Fourth, the majority of participants did not 
correctly guess their treatment allocation at follow-up, 
suggesting blinding was successful (see online supple-
mentary figures 1 and 2). Lastly, the rTMS was individ-
ualised through the use of neuronavigation and a wide 
range of measures to assess relevant clinical outcomes 
were used.
In terms of limitations, the duration of the follow-up 
period was relatively short.11 Our choices regarding 
the rTMS protocol and target brain area (left DLPFC) 
were theoretically, evidentially and practically based12; 
however, the optimal brain areas to target and the rTMS 
protocols to administer in SE-AN are unknown. We used 
a shorter illness duration (minimum of 3 years) than 
what is commonly used to define SE-AN (eg, 7 years19), 
but nonetheless managed to recruit participants with a 
long-standing illness who had typically received several 
previous courses of intensive treatment. Our attempts to 
keep researchers blind to treatment allocation were only 
partly successful; approximately 20% of rTMS sessions 
were delivered by an unblinded researcher, and another 
researcher correctly guessed treatment allocation of 
participants.
strengths and limitations in relation to other studies
Research into treatments for people with SE-AN is 
limited.36 In addition to this study, there have only been two 
trials with a focus on SE-AN. The first of these assessed the 
efficacy of 30 sessions of cognitive behavioural therapy for 
AN compared with specialist supportive clinical manage-
ment in 63 patients.6 Between-group differences in clin-
ical outcomes were minimal. Within-group assessments 
showed small to moderate effect sizes for BMI change 
and medium to large for ED symptoms, depression and 
quality of life from baseline to end of treatment and to 
6 month and 12 month follow-up. The second study inves-
tigated the effects of 4 weeks of a synthetic cannabinoid 
agonist (dronabinol) versus placebo as an adjunct to a 
multimodal treatment combining psychotherapy with 
nutritional interventions in 25 patients with SE-AN.7 
Dronabinol produced significantly greater short-term 
weight gain than placebo, but changes in ED symptoms 
were minimal during the study period. No follow-up 
data were reported. In both of these studies, treatment 
drop-out rates were low, as in the current study, high-
lighting the desire of people with SE-AN to participate in 
novel treatments.
Implications for future research
Building on the present study, a large-scale multicentre 
RCT of real versus sham rTMS as an adjunct to TAU 
with a similar design should be considered. Such a trial 
should include a longer follow-up period (eg, 6 months 
and 12 months) to assess the persistence or otherwise of 
rTMS effects. This is also of importance given that neuro-
plastic changes develop over time.40 For example, studies 
of deep brain stimulation in AN have shown that in treat-
ment responders, changes in mood predate those in ED 
symptoms by several months (eg, 41). Relatedly, it would be 
desirable to include multimodal assessment of comorbidi-
ties, for example, using a combination of semi-structured 
interviews, observed-rated measures and self-reports. 
Second, an assessment of the cost-effectiveness of estab-
lishing rTMS as a treatment option for SE-AN should be 
carried out. Inclusion of inpatients with SE-AN in a future 
trial would be desirable, as it would be easier for them to 
attend daily sessions. This might also allow inclusion of 
patients with a BMI <14 kg/m2, given that inpatients have 
regular medical monitoring and that their food intake is 
more regular than that of community-dwelling patients.
Several questions need to be considered in future 
research of rTMS in SE-AN. The optimal brain areas to 
target and the rTMS protocols for SE-AN are not known. 
 o
n
 10 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021531 on 16 July 2018. Downloaded from 
10 Dalton B, et al. BMJ Open 2018;8:e021531. doi:10.1136/bmjopen-2018-021531
Open access 
High-frequency rTMS targeting the DLPFC was chosen 
for the current study as it was hypothesised that this would 
remediate the hypoactivity observed in AN in response to 
symptom provocation, cognitive flexibility and set-shifting 
tasks, and thus rebalance cognitive control and reward 
systems.12 It was also selected given the strong evidence 
base for high-frequency DLPFC rTMS in other neuro-
circuit-based disorders (eg, treatment-resistant depres-
sion42). Following on from research in depression, the use 
of low-frequency rTMS or intermittent theta burst stimu-
lation (iTBS) in comparison with high-frequency rTMS 
might be tested. Low-frequency rTMS is thought to have 
fewer side effects and be more well tolerated, and iTBS 
would substantially reduce treatment time and participant 
burden. In the depression literature, it appear that both 
of these have similar levels of efficacy to high-frequency 
rTMS.43–46 Future studies should also consider rTMS as an 
adjunct to psychological therapies.47 Other neuromodu-
lation treatments in combination with cognitive interven-
tions have shown promise,48 49 and so, addition of rTMS 
to structured psychotherapy or cognitive training tasks in 
SE-AN may help increase its efficacy.12 Finally, additional 
work on neural and neurocognitive mechanisms of action 
of rTMS and the cost-effectiveness of this treatment are 
necessary.
COnClusIOn
In this feasibility RCT, rTMS was safe and well toler-
ated. This study provides preliminary evidence for the 
therapeutic potential of rTMS treatment in communi-
ty-dwelling SE-AN as an adjunct to TAU. It suggests that 
it is feasible to conduct a future larger scale therapeutic 
RCT with a sham-controlled design to establish/confirm 
the therapeutic efficacy of rTMS in AN. The findings 
from this trial will inform a future large-scale RCT with 
respect to decisions on primary outcome measures and 
other aspects of protocol development, such as sample 
size, design, location and number of research centres. 
Future studies should include a longer follow-up period 
and a formal assessment of cost-effectiveness. Consider-
ation should also be given to use of alternative stimulation 
protocols (eg, low-frequency rTMS) and the combination 
of rTMS and ED-specific therapies/tasks to maximise 
impact on ED and mood.
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